CXCR4 and neoplasm: To date, oncology pre-clinical in vivo studies for CXCR4-targeting antibodies consist of human CXCR4+ tumor cells implanted or infused in immunocompromised mice or the use of anti-mouse CXCR4 “surrogate” antibodies in the case of mouse syngeneic tumors and tumor-prone genetic models.